Use of exenatide and liraglutide in Denmark: A drug utilization study

European Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2014, Pages 205-214

  Pottegård, Anton ^a   Bjerregaard, Bine Kjøller ^b   Larsen, Michael Due ^a   Larsen, Kasper Søltoft ^a   Hallas, Jesper ^a   Knop, Filip K ^c   Moreno, Søren Ilsøe ^d  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d Danish Health and Medicines Authority   (Denmark)

Author keywords

Denmark; Diabetes mellitus; Drug utilization; GLP 1; Prescribing

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; DENMARK; DIABETES MELLITUS, TYPE 2; DRUG UTILIZATION; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; VENOMS; YOUNG ADULT;

EID: 84895074422     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1595-4     Document Type: Article

References (42)

1. Danish Centre for Evaluation and Health Technology Assessment (2005) Type 2 diabetes. Health technology assessment of screening diagnosis and treatment. Dan Health Technol Assess 7(1)
2. Carstensen B, Kristensen JK, Ottosen P, Borch-Johnsen K (2008) The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia 51:2187-2196
3. Stovring H, Andersen M, Beck-Nielsen H, Green A, Vach W (2003) Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 362:537-538
4. Green A, Emneus M, Christiansen T, Bjørk S, Kristensen J (2006) The social impact of diabetes mellitus and diabetes care. Report 3: Type 2 diabetes in Denmark year 2001. SDU Health Econ Papers 2
5. Institute for Rational Pharmacotherapy The Danish College of General Practitioners and the Danish Endocrine Society (2011) Guidelines for type-2 diabetes [in Danish]
6. The Danish College of General Practitioners (2012) Clinical guideline for primary care: type 2-diabetes - a metabolic syndrome [in Danish]
7. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865
8. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S et al (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399
9. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS et al (2008) Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 168:2070-2080
10. Roussel R, Travert F, Pasquet B, Wilson PW, Smith SC Jr, Goto S et al (2010) Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 170:1892-1899
11. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al (2009) Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:84-90
12. Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N et al (2013) Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study. Diabetes Obes Metab 15:204-212
13. Bergenstal RM, Wysham C, Macconell L, Malloy J, Walsh B, Yan P et al (2010) Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 376:431-439
14. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S et al (2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375:1447-1456
15. Meier JJ (2012) GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8:728-742
16. National Collaborating Centre for Chronic Condition (2008) Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). Royal College of Physicians, London
17. Epidemiology FL (2000) When an entire country is a cohort. Science 287:2398-2399
18. Thygesen LC, Ersboll AK (2011) Danish population-based registers for public health and health-related welfare research: introduction to the supplement. Scand J Public Health 39:8-10
19. Kildemoes HW, Sorensen HT, Hallas J (2011) The Danish National Prescription Registry. Scand J Public Health 39:38-41
20. WHO Collaborating Centre for Drug Statistics Methodology (2012) Guidelines for ATC classification and DDD assignment 2013, Oslo
21. Gaist D, Sorensen HT, Hallas J (1997) The Danish prescription registries. Dan Med Bull 44:445-448
22. Pedersen CB (2011) The Danish Civil Registration System. Scand J Public Health 39:22-25
23. Institute for Rational Pharmacotherapy (2011) The national recommendation list: ATC A10B blood glucose lowering drugs, excl. insulins [in Danish]
24. Blonde L, Klein EJ, Han J, Zhang B, Mac SM, Poon TH et al (2006) Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 8:436-447
25. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD (2004) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27:2628-2635
26. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH et al (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29:139-153
27. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH et al (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374:39-47
28. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100
29. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A et al (2003) Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 26:2370-2377
30. Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS et al (2005) Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28:1083-1091
31. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S et al (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 52:2046-2055
32. Zinman B, Hoogwerf BJ, Duran GS, Milton DR, Giaconia JM, Kim DD et al (2007) The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 146:477-485
33. The Danish National Institute for Health Data and Disease Control (Statens Serum Insititut). Medstat.dk; Cited 6/6/2013. Available from: www.medstat.dk/en
34. The Norwegian Institute of Public Health. legemiddelforbrug.no. Accessed 6 June 2013. Available from: www.legemiddelforbruk.no
35. The Swedish National Board of Health and Welfare (Socialstyrelsen). Statistikdatabas för läkemedel. Accessed 6 June 2013. Available from: http://www.socialstyrelsen.se/statistik/statistikdatabas/lakemedel
36. Finnish Medicines Agency (fimea). Lääketurvallisuus ja lääkeinformaatio: Kulutustiedot. Accessed 6 June 2013. Available from: www.fimea.fi/laaketieto/kulutustiedot
37. Icelandic Medicines Agency (IMA). Drug consumption in Iceland 2008-2012. Accessed 6 June 2013. Available from: www.imca.is/imca/statistics/nr/235
38. Danish Regions. Regioner.dk. Accessed 13 August 2013. Available from: http://www.regioner.dk/in+english
39. Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY et al (2011) Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 154:103-112
40. EMA. Summary of Product Characteristics - Byetta. Accessed 8 November 2012. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000698/WC500051845.pdf
41. Ha C, Ullman TA, Siegel CA, Kornbluth A (2012) Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol 10:1002-1007
42. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247-254